Evidence map›Paper›PMID 33190211›Full record

SynthesisGeroScience2021

Association between telomere length, frailty and death in older adults.

Mariam El Assar, Javier Angulo, José A Carnicero, Stefan Walter, Francisco J García-García, Fernando Rodríguez-Artalejo, Leocadio Rodríguez-Mañas

Open access · bronzeAbstract readMeta-Analysis
In one paragraph

Synthesis in GeroScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Mariam El AssarFundación de Investigación Biomédica del Hospital Universitario de Getafe, Getafe, Spain.
Javier AnguloCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain.
José A CarniceroFundación de Investigación Biomédica del Hospital Universitario de Getafe, Getafe, Spain.
Stefan WalterFundación de Investigación Biomédica del Hospital Universitario de Getafe, Getafe, Spain.
Francisco J García-GarcíaHospital Virgen del Valle, Complejo Hospitalario de Toledo, Toledo, Spain.
Fernando Rodríguez-Artalejo *Department of Preventive Medicine and Public Health, Universidad Autónoma de Madrid/IdiPaz, CIBERESP, and IMDEA Food Institute, Madrid, Spain.
Leocadio Rodríguez-Mañas *Fundación de Investigación Biomédica del Hospital Universitario de Getafe, Getafe, Spain. leocadio.rodriguez@salud.madrid.org.
Instituto de Salud Carlos III · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable · ESHospital Universitario de Getafe · ESHospital Universitario Ramón y Cajal · ESHospital Virgen del Valle · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frailty is considered a clinical marker of functional ageing. Telomere length (TL) has been proposed as a biomarker of biological age but its role in human ageing is controversial. The main aim of the study was to evaluate the longitudinal association of TL with incident frailty and mortality in two cohorts of Spanish community-dwelling older adults. TL was determined at baseline in blood samples from older adults included in Toledo Study for Healthy Aging and ENRICA cohorts while frailty was determined by frailty phenotype (FP) at baseline and at follow-up (3.5 years). Deaths occurring during follow-up were also recorded. Associations of TL with frailty and mortality were analysed by logistic regression with progressive adjustment. Data were separately analysed in the two cohorts and in all subjects by performing a meta-analysis. TL was not different between frail and non-frail subjects. Longer telomeres were not associated with lower risk of prevalent frailty. Similarly, TL at baseline failed to predict incident frailty (OR: 1.04 [0.88-1.23]) or even the development of a new FP criterion (OR: 0.97 [0.90-1.05]) at follow-up. Lack of association was also observed when analysing the development of specific FP criteria. Finally, while frailty at baseline was significantly associated with higher risk of death at follow-up (OR: 4.08 [1.97-8.43], p < 0.001), TL did not significantly change the mortality risk (OR: 1.05 [0.94-1.16]). Results show that TL does not predict incident frailty or mortality in older adults. This suggests that TL is not a reliable biomarker of functional age.

Indexed as

FrailtyAgedAgingBiomarkersHumansIndependent LivingTelomereBiomarkersAgeingBiomarkerFrailtyFunctional declineMortalityTelomere

Identifiers

PMID33190211
PMCPMC8110679
OpenAlexW3102735067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.